Vixotrigine
As of the edition of 20 October 2026, Vixotrigine is a small molecule: stopped in 2026; acts on SCN9A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 21, 6 stopped early
- Disease areas
- Nervous system; Mouth and teeth; Hormones; Mental health; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Vixotrigine.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SCN9A | Sodium channel protein type 9 subunit alpha | Q15858 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 13 | 11 | 0 | 2 |
| Phase 2 | 6 | 4 | 0 | 2 |
| Phase 3 | 2 | 0 | 0 | 2 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biogen | Lead sponsor of trials | 2007 to now |